Taysha Gene Therapies Reports to Discontinue its TSHA-120 Program in Giant Axonal Neuropathy
Shots:
- After the feedback from the Type C meeting with the US FDA, the company is terminating the evaluation of TSHA-120 to treat GAN due to challenges related to the feasibility of the study designs to support a BLA submission
- As part of a Type C meeting in Jun 2023, the company submitted a new comprehensive analysis of the totality of data from the natural history and interventional trial comparing functional and biological measurements against a Disease Progression Model
- Additionally, Astellas has declined its exclusive license option agreement with Taysha for this therapy and the evaluation of TSHA-102 in P-I/II study (REVEAL) will be continued in adults and planned pediatric patients
Ref: Taysha Gene Therapies | Image: Taysha Gene Therapies
Related News:- Taysha Gene Therapies’ TSHA-102 Receives the US FDA’s Fast Track Designation for Rett Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
